Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s603. https://doi.org/10.25251/x2k3y515